John E. Pilling, FRCS (CTh), Michael E

Slides:

Advertisements

Similar presentations

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB Martin J. Edelman, MD, Lydia.

Advertisements

Su K. Metcalfe, MD, MPH, Michael T

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia Arman Hasani, MBBS, FRACP, John M. Alvarez,

Treatment of Malignant Pleural Effusion

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer Wolf Köster, MD, Andrea Heider, MD, Norbert.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases Åslaug Helland, MD, PhD, Steinar Solberg,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

A Phase II Study of PF in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207 Paul Wheatley-Price, MBChB, MD, Quincy Chu,

Electronic Updates for JTO Readers

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer Daniel Morgensztern, MD, Saiama.

Serum Thymidine Kinase 1 Activity in the Prognosis and Monitoring of Chemotherapy in Lung Cancer Patients: A Brief Report Benjamin Nisman, PhD, Hovav.

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Role of Integrated 18-Fluorodeoxyglucose Position Emission Tomography-Computed Tomography in Patients Surveillance after Multimodality Therapy of Malignant.

Frank Detterbeck, MD Journal of Thoracic Oncology

A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.

Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327) Primo N. Lara,

Prognostic Factors in Patients with Pathologic T1-2N1M0 Disease in Non-small Cell Carcinoma of the Lung Katsunari Matsuoka, MD, Shinichi Sumitomo, MD,

Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and.

Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma Fauzia Shaikh, MD, Marjorie G. Zauderer,

Does Granulocyte Colony–Stimulating Factor Affect Survival in Patients with Advanced Non-small Cell Lung Cancer? Goulnar Kasymjanova, MD, Harvey Kreisman,

Prolonged Survival in Patients with Lung Cancer with Diabetes Mellitus

Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis.

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) Gregory A. Otterson,

Should Patient-Rated Performance Status Affect Treatment Decisions in Advanced Lung Cancer? Esther Dajczman, RN, MScA, Goulnar Kasymjanova, MD, PhD,

Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer Elaine Y.L. Leung, MB ChB,

Forced Expiratory Volume in One Second as a Prognostic Factor in Advanced Non- small Cell Lung Cancer Jin Hwa Lee, MD, PhD, Eun Mi Song, MD, Yun Su Sim,

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

Does Lymph Node Metastasis Have a Negative Prognostic Impact in Patients with NSCLC and M1a Disease? Chenyang Dai, MD, Yijiu Ren, MD, Dong Xie, MD, PhD,

Clinical Relevance of Our Multimodality Prognostic Score

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

Frequency and Prognostic Significance of Preoperatively Detected Enlarged Regional Lymph Nodes in Patients with Pathological Stage I Non-small Cell Lung.

It’s All in the “Swerve of the Curve”

Silvia Bielsa, MD, José Martín-Juan, MD, José M

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

International Thymic Malignancies Interest Group: A Way Forward

A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 Ramaswamy Govindan, MD, Xiaofei.

European Lung Cancer Conference (ELCC) 2016 Organisation

James D Luketich, Michael E Burt The Annals of Thoracic Surgery

Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis Mariette Baud, MD, Salvatore Strano, MD, PhD, Agnes.

David James Pinato, MD, MRes, Francesco A

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Raja M. Flores, MD The Journal of Thoracic and Cardiovascular Surgery

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell.

Temporal Trends in Long-Term Survival and Cure Rates in Esophageal Cancer: A SEER Database Analysis Attila Dubecz, MD, Isabell Gall, MD, Norbert Solymosi,

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Debby P. M. van den Bogaert, MD, Ellen M

A Review of First-Line Treatment for Small-cell Lung Cancer

Outcome after Pulmonary Metastasectomy: Analysis of 5 Years Consecutive Surgical Resections 2002–2006 Kåre Hornbech, MD, Jesper Ravn, MD, Daniel Andreas.

Mott Frank E. , MD, Sharma Neeraj , MD, Ashley Pandora CHEST

Node-Negative Non-small Cell Lung Cancer: Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy,

Presentation transcript:

Prognostic Factors for Survival after Surgical Palliation of Malignant Pleural Effusion John E. Pilling, FRCS (CTh), Michael E. Dusmet, MD, George Ladas, FRCS, Peter Goldstraw, FRCS Journal of Thoracic Oncology Volume 5, Issue 10, Pages 1544-1550 (October 2010) DOI: 10.1097/JTO.0b013e3181e95cb8 Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Kaplan-Meier survival curve for all patients from the day of palliative procedure. Journal of Thoracic Oncology 2010 5, 1544-1550DOI: (10.1097/JTO.0b013e3181e95cb8) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Kaplan-Meier survival curve for patients with the commonest five pleural malignancies. Journal of Thoracic Oncology 2010 5, 1544-1550DOI: (10.1097/JTO.0b013e3181e95cb8) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Kaplan-Meier survival curve comparing patients with a white cell count ≤12 × 109/liter or >12 × 109/liter. Journal of Thoracic Oncology 2010 5, 1544-1550DOI: (10.1097/JTO.0b013e3181e95cb8) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Kaplan-Meier survival curve comparing patients with a partial pressure of oxygen (Pao2) ≤9.5 kPa or >9.5 kPa. Journal of Thoracic Oncology 2010 5, 1544-1550DOI: (10.1097/JTO.0b013e3181e95cb8) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Kaplan-Meier survival curve comparing patients with a serum albumin ≤35 g/liter or >35 g/liter. Journal of Thoracic Oncology 2010 5, 1544-1550DOI: (10.1097/JTO.0b013e3181e95cb8) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 6 Kaplan-Meier survival curve comparing patients with none, one or two of three, or all three prognostic factors determined by multivariate analysis. Journal of Thoracic Oncology 2010 5, 1544-1550DOI: (10.1097/JTO.0b013e3181e95cb8) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 7 Kaplan-Meier survival curve for all patients with malignant pleural mesothelioma from the day of palliative procedure. Journal of Thoracic Oncology 2010 5, 1544-1550DOI: (10.1097/JTO.0b013e3181e95cb8) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 8 Kaplan-Meier survival curve comparing patients with malignant pleural mesothelioma with none, one or two of three, or all three prognostic factors determined by multivariate analysis. Journal of Thoracic Oncology 2010 5, 1544-1550DOI: (10.1097/JTO.0b013e3181e95cb8) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions